Clinical Trial Update: A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa) [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing disability in anemic elderly patients with kidney disease treated with Procrit (epoetin alfa) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Ortho Biotech Products, L.P. | Conditions: Anemia, Kidney Diseases | Phase 4 | Status: TERMINATED